Last Update 27 Aug 26
Fair value Increased 20%Veeva Just Had a Great Quarter. That's Exactly Why I'm Not Buying More.
Revenue beat. Earnings beat. Guidance raised. Stock popped 9%. And I did the single least exciting thing available to me: nothing. Let me talk you into why that was the right call for me— and why "nothing" isn't the same as "sold."
I. Quick Recap, For Anyone Just Joining
Back in June, my case for Veeva Systems (VEEV) wasn't really about software. It was about the cost of being wrong. Pharmaceutical companies don't casually rip systems out of their clinical trials, regulatory submissions, and safety workflows — doing that is less like switching email providers and more like swapping an engine part mid-flight. That kind of fear is a wonderful thing to own a piece of. It creates switching costs, switching costs create retention, and enough retention starts looking suspiciously like a moat.
At the time, Veeva traded around $167 against a fair value estimate near $320. Great business, ugly price. Exactly the setup I go looking for.
Today, the ugly price action mostly evaporated. Q2 fiscal 2027 revenue hit $928 million, up 18% year over year. GAAP operating income jumped 40%. Management raised full-year guidance. CEO Peter Gassner said Vault CRM had its best quarter ever, and the numbers back him up: more than 180 customers now live on it, including 12 of the top 20 biopharma companies in the world — up from five just this quarter. Veeva Falcon, the new agentic AI platform, is moving fast enough that "accelerated rapidly" undersold it.
The stock jumped roughly 9% after hours, to around $267.
Wonderful. Now comes the weird part: I'm not buying any more of it. I'm also not selling a single share.
II. Good News Is the Sneakiest Kind of Trap
Here's the trap, and it catches smart people constantly: company reports great numbers, stock jumps, and the brain fills in the rest of the sentence for you — the thesis is working, I should buy more. Sometimes that's true. But there's a second question hiding behind the first one, and it's the one that actually matters: at this new price, how much of that good news am I now being asked to pay for?
That's Margin of Safety. My recertified fair value for Veeva is $383.14. At $267, that's a 30.3% discount. Still genuinely attractive.
But I don't stop at raw MOS, because every fair value estimate is a forecast wearing a nametag that says "fact." Forecasts deserve some humility, so I run a second number: Conviction-Weighted MOS. It takes that raw discount and asks a much less flattering question — how much of it do I actually trust, once I account for execution risk, competitive risk, and how much weight the underlying assumptions can really bear?
Veeva's Conviction MOS today: 21.8%. My deployment floor is 25%. It probably clears many investors hurdles, It doesn't clear mine.
Not because something went wrong. Because something went right, and the market charged me for it faster than my confidence could catch up.
III. Watch the Two Numbers Move at Different Speeds
Here's the whole story in one table:
My fair value estimate moved less than 1%. The stock moved 9%. That gap — a great quarter making the company more valuable and the stock less attractive to buy, simultaneously — is not a contradiction. It's just two clocks running at different speeds, and most people only ever check the one on the stock ticker.
IV. "Not a Buy" Is Not the Same Sentence as "Sell"
This is where I think even good investors trip. A stock crosses below your buying threshold and suddenly people talk like there's a trapdoor under it. There isn't. Buying and selling aren't opposite ends of the same see-saw — there's supposed to be a wide, boring stretch of no-man's-land in between, and mine is currently doing its job.
Not cheap enough to add. Still about 43% below my certified fair value before crediting the business with a single dollar of further growth. Selling here because my buy signal turned off would be its own kind of error — I'd be answering a completely different question than the one that was actually asked.
V. The Position Has Already Made Money. That's a Liability, Not a Reason.
My Veeva shares are up substantially from where I first bought them (+59.7%), and that fact is trying to influence a decision it has no business being anywhere near. "I've made enough" and "after a run like this, I should trim" both feel like discipline. They're actually just your own gain talking, dressed up as strategy.
The stock doesn't know my cost basis. The company has never once checked my account balance before reporting earnings. The only question that's actually relevant is the one that ignores my history entirely: from today's price, how much return is left on the table? My answer: still enough to own. Not enough to add. That's a perfectly legitimate zip code for a stock to live in, and pretending it isn't is how good investors talk themselves into unforced errors.
VI. What Would Actually Get Me Buying Again
Price. That's it. If Veeva gives back enough of this rally while the business stays intact, Conviction MOS climbs back over my floor on its own — same company, same moat, same CEO, cheaper ticket. I don't need a press release. I need the on-sale rack.
VII. What Would Actually Get Me Selling
Not "the stock went up," which is my Rotation Engine's least favorite reason to do anything. It sells when the return left in a position stops deserving the capital tied up in it — which usually means Veeva creeping close to its own fair value while something else sits 35-45% below an equally defensible one. At that point I'm not fleeing Veeva. I'm choosing between two good uses of the same dollar. We are nowhere near that conversation today.
VIII. The Lesson Was Never Really About Veeva
A 9% pop feels like it should demand a reaction. It doesn't. The market hands you a price every second of every day; the business hands you actual information about four times a year. Your job was never to react to either one on its own — it's to hold them up against each other and see which one's lying.
Today, Veeva gave me a better business. The market gave Veeva a bigger price tag. My fair value moved a little. My margin of safety moved a lot. And the decision that fell out of that math wasn't buy, and it wasn't sell. There are three buttons in this game for a reason, and the one people forget how to press is the one that looks, from the outside, exactly like doing nothing.
This is not financial advice.
Disclosure: I hold shares of Veeva Systems (VEEV). Figures are drawn from Veeva's fiscal Q2 2027 earnings release (August 26, 2026) and verified against the company's own press release language. Fair value and Conviction MOS estimates are my own analysis and may be wrong. Do your own due diligence.
Investors often look for artificial intelligence winners in the obvious places: semiconductors, hyperscalers, and general-purpose software platforms.
But some of the most durable AI opportunities may sit in far less glamorous places—inside the regulated workflows where a mistake is not merely inconvenient, but potentially delays a drug trial, a regulatory submission, or a therapy reaching patients.
That is the central investment thesis for Veeva Systems (NYSE: VEEV).
Veeva is not simply another cloud-software company selling productivity tools. It has built deeply embedded software across the life-sciences value chain: clinical trials, regulatory submissions, drug safety, quality, medical affairs, and commercial operations. Its systems sit close to the operational core of pharmaceutical and biotechnology companies.
The interesting question for investors is not whether Veeva is a good business. The recent numbers make that relatively clear.
The real question is whether the market is underestimating how durable its customer relationships may be—and whether AI can become a meaningful second act rather than merely a feature.
The moat is not software. It is the cost of being wrong.
Most enterprise software can be replaced with enough time, money, and executive determination.
Life-sciences software is different.
Drug companies operate in an environment where data integrity, audit trails, controlled workflows, documentation, and regulatory compliance are essential. Moving systems is not simply an IT project. It can involve years of validation work, operational disruption, and material regulatory risk.
That creates a powerful economic principle investors should understand:
Switching costs are strongest when changing vendors creates professional, operational, or regulatory danger.
Veeva’s products are woven into workflows that pharmaceutical companies cannot casually interrupt. Clinical documents, safety reports, quality records, regulatory submissions, and commercial content often remain in the system for many years. Once these processes are standardized around a platform, changing it becomes increasingly unattractive.
That does not make Veeva invulnerable. No software company is. But it does mean the company’s customer relationships may be far more resilient than those of a typical SaaS vendor.
Its approximately 99% customer retention rate supports that conclusion, although investors should continue to monitor retention, competitive displacement, and customer-consolidation trends rather than treating the figure as permanent.
The financial engine remains unusually strong
Veeva’s first-quarter fiscal 2027 results showed why the market continues to treat the company as a high-quality compounder.
Revenue reached $882.9 million, up 16% year over year, while subscription revenue grew 15%. The company also generated GAAP operating income of $273.1 million and non-GAAP operating income of $395.4 million. (Veeva Investor Relations)
These numbers matter for more than headline growth.
They suggest that Veeva is maintaining healthy expansion while preserving substantial profitability. That combination is rare. Many software companies can grow quickly but need to spend heavily to do so. Others have impressive margins but lack a credible path to sustained growth.
Veeva has historically combined both traits: recurring subscription revenue, mission-critical products, attractive operating leverage, and a net-cash balance sheet. The company’s fiscal 2027 guidance calls for total revenue of roughly $3.64 billion and non-GAAP operating income of approximately $1.61 billion. (Veeva Systems)
For long-term investors, that creates a useful framework:
- Is the installed base durable?
- Can Veeva keep expanding its product footprint inside that installed base?
- Can margins remain strong as the business scales?
- Does the current valuation leave room for attractive returns?
The first three questions appear to have increasingly favorable answers. The fourth is where discipline matters.
Falcon may be the next chapter—but investors should distinguish promise from proof
Veeva’s emerging AI strategy is called Falcon, an agentic platform designed to bring AI capabilities into life-sciences workflows.
The strategic appeal is straightforward. Generic AI tools can summarize documents or generate text. But pharmaceutical companies require AI that can operate within highly structured, compliant workflows involving clinical development, regulatory processes, safety, quality, and medical review.
Veeva’s advantage is not that it invented AI. Its advantage may be that it already owns the workflow layer where AI can become useful.
The company announced Falcon as an agentic platform for drug development, with early-adopter availability planned for November 2026. (Veeva Investor Relations) More recently, Veeva also announced Falcon MLR, an AI-enabled offering intended to reduce manual work and shorten the medical, legal, and regulatory review cycle for promotional content. (Veeva Investor Relations)
This is important because AI monetization is often difficult when companies must convince customers to adopt an entirely new platform.
Veeva does not face that same challenge. It already has relationships, workflows, data structures, and compliance processes embedded in its customers’ operations.
That creates a potentially attractive setup:
Veeva may not need to win the AI platform war. It may only need to make AI increasingly valuable inside the systems customers already rely upon.
Still, Falcon should be treated as an upside option—not yet a fully proven earnings engine. Investors should watch adoption, pricing, customer outcomes, recurring revenue contribution, and evidence that AI improves retention or expands Veeva’s share of customer technology budgets.
Valuation: a quality company still requires a price discipline
A great company can still be a poor investment if purchased at an excessive valuation.
My valuation framework estimates a fair enterprise value of roughly $320 per share, based on approximately $1.4 billion in projected free cash flow, 16% growth over years one through five, 12% growth over years six through ten, a 3.5% terminal-growth rate, a 9% discount rate, and roughly $4.5 billion of net cash. This is an investor estimate, not company guidance.
Using the June 12 reference price of approximately $167, that framework implied a raw margin of safety near 48%. At a more conservative accumulation level around $150, the modeled margin of safety expanded above 50%.
The important lesson is not that $320 is a precise destination. No discounted-cash-flow model deserves that degree of confidence.
The lesson is that quality investors should separate two decisions:
- Is this a business worth owning for many years?
- At what price does the expected return justify committing capital?
Veeva appears to clear the first hurdle convincingly. The second depends on one’s assumptions about growth, AI monetization, competitive pressure, and required return.
Risks investors should not ignore
The Veeva thesis is strong, but it is not risk-free.
First, pharmaceutical mergers can temporarily slow technology spending as companies consolidate systems and defer decisions. In the long run, larger combined organizations may need more workflow standardization, but the short-term effects can still pressure growth.
Second, AI remains an execution story. Falcon may become a meaningful growth driver, but investors should not assume that every AI announcement produces durable revenue.
Third, competition remains real. Veeva’s transition away from Salesforce in commercial software has reduced one source of uncertainty, but the company must continue proving that its newer products can maintain adoption and customer satisfaction.
Finally, Veeva is not a distressed bargain. It is a premium-quality software business. Premium businesses can still suffer sharp price declines when growth expectations reset, enterprise spending weakens, or valuation multiples compress.
The bottom line
Veeva’s attraction is not simply that it sells software to pharmaceutical companies.
Its attraction is that it sits inside workflows where reliability, compliance, historical data, and institutional trust matter enormously. Those characteristics can produce customer relationships that are unusually long-lived and difficult to displace.
The recent financial results show that the core business remains healthy. Falcon creates a credible opportunity to add AI-driven monetization across an existing life-sciences customer base. And the company’s balance sheet and profitability give it room to invest through market cycles.
For investors, Veeva is best understood as a high-quality compounding business whose long-term value may be driven less by dramatic quarterly surprises and more by the gradual deepening of its role as the operating system for life sciences.
The key is patience—and valuation discipline.
Disclosure: I own Veeva shares and may increase my position if the share price reaches levels that provide a larger margin of safety. This article reflects my personal investment research and is not financial advice.
Have other thoughts on Veeva Systems?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Comments
0 commentsDisclaimer
The user John_Eric has a position in NYSE:VEEV. Simply Wall St has no position in any of the companies mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The author of this narrative is not affiliated with, nor authorised by Simply Wall St as a sub-authorised representative. This narrative is general in nature and explores scenarios and estimates created by the author. The narrative does not reflect the opinions of Simply Wall St, and the views expressed are the opinion of the author alone, acting on their own behalf. These scenarios are not indicative of the company's future performance and are exploratory in the ideas they cover. The fair value estimates are estimations only, and does not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that the author's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
